$ News

Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties

Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan

Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration

Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer

Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan

Eagle Pharmaceuticals Implements Stockholder Rights Plan

Union Square Park Capital Management's Strategic Acquisition of Eagle Pharmaceuticals Shares

Top Midday Decliners

Eagle Pharmaceuticals in Default Amid Delays in Financial Report Filings, Braces for Delisting

Eagle Pharmaceuticals Navigates Financial Uncertainty and Defaults

Eagle Pharmaceuticals says in default under credit agreement

Eagle Pharmaceuticals commences review to evaluate range of alternatives

Eagle Pharmaceuticals delays annual report on Form 10-K filing

Eagle Pharmaceuticals sees 'one or more' material weaknesses

Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

Eagle Pharmaceuticals Struggles with Financial Compliance and Nasdaq Listing

Eagle Pharmaceuticals receives delisting notification from Nasdaq